Thu.Jun 13, 2024

article thumbnail

Pharmacists Can Help Alleviate Men’s Mental Health Crisis

Drug Topics

Patrick Alonso, PharmD, CPh, discusses how pharmacists can support men dealing with mental health issues and lifestyle changes he recommends to male patients to improve overall health.

201
201
article thumbnail

FDA Approves Tralokinumab-ldrm Autoinjector for Adults With Atopic Dermatitis

Pharmacy Times

The autoinjector will provide another option for adults in addition to the prefilled syringe that is currently available.

FDA 156
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Global health leader critiques ‘ineptitude’ of U.S. response to bird flu outbreak among cows

STAT

LONDON — Seth Berkley, a longtime and widely respected global health leader , said Thursday that it has been “shocking to watch the ineptitude” of the U.S. response to the avian influenza outbreak among dairy cattle , adding his voice to a chorus of critics. In a presentation in London about vaccine development, Berkley, the former CEO of Gavi, the Vaccine Alliance, raised the issue of H5N1 bird flu when discussing whether the world was ready for another pandemic following i

Vaccines 145
article thumbnail

Implications for Pharmacies Navigating Shared Clinical Decision-Making in Vaccination

Pharmacy Times

The SCDM model demands more than the traditional roles assigned to pharmacists, requiring an enhanced level of patient engagement, medical knowledge, and legal authority to implement effectively

Vaccines 149
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

In dribs and drabs, USDA reports suggest containing bird flu outbreak in dairy cows will be challenging

STAT

The U.S. Department of Agriculture released two reports Thursday that lay out what has been learned about how H5N1 bird flu is moving among dairy cow herds in the United States. The reports do not shed much new light on the situation. Instead, they sum up what is known: that the outbreak was probably the result of a single “spillover” of the virus from wild birds into a dairy herd, likely late last year, and that movement of cows, farmworkers, and shared equipment appears to be res

145
145
article thumbnail

Modifier gene therapy – clinical development and manufacturing considerations

European Pharmaceutical Review

Tell us about Ocugen’s lead programme, OCU400. What’s the latest and what’s next? OCU400 is a modifier gene therapy aimed at treating retinitis pigmentosa and Leber congenital amaurosis (LCA). In April 2024, Ocugen received US Food and Drug Administration (FDA) clearance to initiate the Phase III liMeliGhT clinical trial for OCU400 for retinitis pigmentosa.

More Trending

article thumbnail

Overcoming Bias: How Cultural Competence Improves Patient Care

Drug Topics

In a world rich with diversity, pharmacists need to understand how varied backgrounds and special needs can impact a patient’s decisions in managing their health and medication protocols.

article thumbnail

Novel Treatments Could Turn the Tide for Alzheimer Disease

Pharmacy Times

Anti-amyloid antibody administration decreased plaque volume in clinical trials of patients with early AD, indicating that passive immunotherapies could be a promising treatment for the disease.

132
132
article thumbnail

Report: Medicare Advantage quality ratings to get new calculations

Fierce Healthcare

The Centers for Medicare & Medicaid Services (CMS) appears poised to rework Medicare Advantage (MA) quality ratings for this year, The Wall Street Journal

129
129
article thumbnail

STAT+: Telehealth startup Done’s top leadership arrested under fraud charges

STAT

The CEO and clinical president of a closely watched telehealth startup prescribing ADHD-medication Adderall online have been arrested and charged with fraud, the Justice Department announced today. Done founder Ruthia He, and clinical president David Brody, were arrested in Los Angeles and San Rafael, California respectively. They were charged with allegedly taking part in a scheme to distribute controlled substances online and submitting false and fraudulent reimbursement claims for stimulant p

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Telehealth startup Done's CEO and clinical president arrested, charged with fraud

Fierce Healthcare

The CEO and clinical president of telehealth startup Done have been arrested and charged with fraud, accused by federal authorities of participating in a scheme to distribute Adderall online. | According to the DOJ, Done's CEO and clinical president allegedly arranged the prescription of 40 million Adderall pills as well as other stimulants, generating more than $100 million in revenue.

128
128
article thumbnail

STAT+: Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried

STAT

LONDON — A major shakeup in how the benefits of medicines are assessed in Europe is looming, and developers of treatments like gene therapies are already arguing that what they see as flaws in the new system could entrench the issues they’ve had getting their products to patients. Starting next year, there will be a new, continent-level review of a drug’s effectiveness compared to what else is on the market.

126
126
article thumbnail

Community Pharmacists Are Uniquely Positioned to Address Social Determinants of Health

Pharmacy Times

Listen closely and ask clarifying questions to best address patient challenges.

123
123
article thumbnail

STAT+: FDA gets pointed input on ‘optimizing’ advisory committee panels

STAT

The day an FDA advisory committee met to weigh the merits of an experimental treatment for amyotrophic lateral sclerosis was one of the worst of Mitze Klingenberg’s life.  Her son Matt had benefited, she said, from an ALS treatment under review for approval by the Food and Drug Administration. However, the expert panel voted against the therapy on that day, Sept. 27, 2023.

FDA 124
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

PrimeRx Wins 3 Stevie® Awards in 2024 American Business Awards® Honors

Pharmacy Times

The awards were announced last night at the ABA gala held at the Marriott Marquis in New York City.

123
123
article thumbnail

The comeback story of Decent Health and how it aims to make health plans more affordable

Fierce Healthcare

There have been many twists and turns in Decent Health's six-year journey as a startup. | Decent has relaunched with a new approach to build level-funded health plans around direct primary care to serve small and medium-sized companies.

122
122
article thumbnail

Opinion: What happened to obesity after Chile slew Tony the Tiger?

STAT

“In Sweeping War on Obesity, Chile slays Tony the Tiger.” So read the headline of a front-page story in The New York Times in 2018 on a dramatic step Chile was taking to fight obesity. With some of the highest obesity levels in South America, the country had begun enforcing strict regulations on Frosted Flakes and other foods that exceeded set thresholds for sugar, calories, salt, or saturated fat in 2016.

119
119
article thumbnail

Blue Cross Blue Shield of Michigan pulling back on GLP-1 coverage

Fierce Healthcare

Blue Cross Blue Shield of Michigan will pull back on coverage for GLP-1 drugs amid rising costs for these products. | Blue Cross Blue Shield of Michigan will pull back on coverage for GLP-1 drugs amid rising costs for these products.

120
120
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Launch Excellence: Moments of Truth

pharmaphorum

Explore the key moments of truth in launch excellence for MSLs and commercial teams in this informative white paper. Gain valuable insights and strategies for successful launches.

118
118
article thumbnail

Pfizer expects 8 blockbuster cancer drugs to come from each of 4 focus areas: exec

Fierce Pharma

Pfizer's oncology division plans to have eight blockbusters by 2030, with contributions from each of its four focused therapeutic areas.

116
116
article thumbnail

The B2C prescription: Marketing lessons for B2B pharma companies

pharmaphorum

Learn valuable marketing lessons for B2B pharma companies by examining successful strategies used in the B2C prescription market, including over-the-counter (OTC) products and interactions with healthcare professionals (HCPs).

116
116
article thumbnail

Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents

The FDA Law Blog

By Sara W. Koblitz — As we have noted for the last year or so, the FTC has been on a mission to clean up the Orange Book by removing what it deems to be “improper” patents. The FTC has put out policy statements, challenged patent listings, tapped Congress, appeared on talk shows, and filed amicus briefs all in the span of the last 8 months. It seems like all that work is paying off.

Dosage 116
article thumbnail

Mahana’s DTx for IBS gets permanent reimbursement in Germany

pharmaphorum

Mahana Therapeutics has granted permanent reimbursement in Germany for its Cara Care digital therapeutic for irritable bowel syndrome

116
116
article thumbnail

Listen: Duchenne gene therapy setback, Alzheimer’s drug endorsement & why a STAT reporter buys weed (for journalism)

STAT

On this week’s episode of “The Readout LOUD,” our STAT colleague Nicholas Florko joins us to explain what it means to be a reporter who writes about the commercial determinants of health. Hint: Florko’s most recent stories focused on weed, vapes and raw milk. And instead of being chained to a desk, he often drives around to convenience stores and buy bad stuff — all in the name of good journalism.

FDA 113
article thumbnail

Future of Pfizer’s Duchenne gene therapy in doubt

pharmaphorum

Pfizer is “evaluating next steps” for its Duchenne muscular dystrophy (DMD) gene candidate after it failed a phase 3 trial

115
115
article thumbnail

FDA Approves Dapagliflozin to Treat Pediatric Patients with Type 2 Diabetes

Drug Topics

The therapy from AstraZeneca is indicated to improve glycemic control in patients aged 10 years or older.

FDA 112
article thumbnail

AbbVie licenses FutureGen IBD drug in $1.7bn deal

pharmaphorum

AbbVie agrees $1.

114
114
article thumbnail

California employee retirement system flips to Blue Shield of CA for PPO coverage

Fierce Healthcare

The California Public Employees’ Retirement System (CalPERS) has named Blue Shield of California as the only health plan in its preferred provider organization.

112
112
article thumbnail

Four takeaways from ASCO24

pharmaphorum

Last weekend, editor-in-chief Jonah Comstock attended the annual conference of the American Society of Clinical Oncologists in Chicago, an event renowned for announcing significant advancements in cancer treatment.

112
112
article thumbnail

Side effects of meloxicam in dogs

The Checkup by Singlecare

Meloxicam , brand name Metacam, is a prescription medication that falls into the class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). The U.S. Food and Drug Administration (FDA) approves meloxicam for managing pain and inflammation in cats and dogs in veterinary medicine. “In dogs, meloxicam is prescribed primarily to relieve pain and inflammation associated with osteoarthritis (joint pain), neurological disease, or to alleviate discomfort after surgery,” says Mat Glassman, MB

article thumbnail

WuXi buoyed as BIOSECURE Act is left out of US spending bill

pharmaphorum

Shares in WuXi Biologics and WuXi AppTec rose after the BIOSECURE Act was omitted from legislation due to be followed up in congress.

111
111
article thumbnail

32 bipartisan state attorneys general ask Supreme Court to take up Oklahoma PBM case

Fierce Healthcare

More than half of the country’s state attorneys general have banded together to get the Supreme Court’s input on pharmacy benefit manager (PBM) regulation. | The attorneys general coalition said that an appellate court's position on an Oklahoma law conflicts with the decision the top court handed down in 2020, creating ambiguity over the reach of state PBM regulation.

106
106
article thumbnail

With phase 3 miss, Pfizer's DMD candidate is no threat to Sarepta's Elevidys ahead of key label expansion: analysts

Fierce Pharma

With a phase 3 miss following a fatality in a related study and marking what analysts are calling the “final nail” in Pfizer’s Duchenne muscular dystrophy (DMD) gene therapy coffin, Sarepta Therape | With a phase 3 miss and severe safety signals, Pfizer's Duchenne muscular dystrophy gene therapy candidate is no competition to Sarepta's established Elevidys, according to analysts.

Labelling 105